Meeting
2022 ASCO Annual Meeting
Outcomes of appendiceal cancer treated at a state peritonectomy service.
Authors
Madeleine Cornelia Strach
Department of Medical Oncology, Chris O'Brien Lifehouse, Sydney, Australia
Madeleine Cornelia Strach , Nabila Ansari , Cherry Koh , Michael Solomon , Lisa Horvath , Kate Mahon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Other Colorectal and Anal Cancer
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 3629)
DOI
10.1200/JCO.2022.40.16_suppl.3629
Abstract #
3629
Poster Bd #
422
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
DKN-01 plus bevacizumab and chemotherapy as second-line (2L) investigational therapy in advanced microsatellite stable (MSS) colorectal adenocarcinoma (CRC): DeFianCe trial.
First Author: Meredith Pelster
Poster
2022 ASCO Annual Meeting
Functional impact of somatic mutations in early-onset (EO) versus average onset (AO) microsatellite stable (MSS) stage III colorectal cancer (CRC).
First Author: Emily Harrold
Poster
2019 ASCO Annual Meeting
Survival according to mutations in BRAF, KRAS, or microsatellite instability (MSI-H) after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal metastases from colorectal cancer.
First Author: Stein G Larsen
Poster
2019 ASCO Annual Meeting
BRCA1 genetic variant to predict survival in metastatic colorectal cancer (mCRC) patients (pts) treated with FOLFIRI/bevacizumab (bev): Results from phase III TRIBE and FIRE-3 trials.
First Author: Madiha Naseem